APGE
Apogee Therapeutics, Inc. NASDAQ$83.55
Mkt Cap $5.2B
52w Low $34.34
80.7% of range
52w High $95.31
50d MA $78.81
200d MA $61.84
P/E (TTM)
-19.1x
EV/EBITDA
-15.7x
P/B
5.4x
Debt/Equity
0.0x
ROE
-28.3%
P/FCF
-19.7x
RSI (14)
—
ATR (14)
—
Beta
1.02
50d MA
$78.81
200d MA
$61.84
Avg Volume
968.5K
About
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-l…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | AMC | -1.05 | -1.03 | +1.9% | 70.92 | -3.0% | -3.4% | +2.0% | +0.0% | +3.0% | +5.7% | — |
| Nov 10, 2025 | AMC | -1.12 | -1.11 | +0.9% | 56.77 | -0.1% | +10.9% | +11.2% | +10.9% | +15.4% | +14.2% | — |
| Aug 11, 2025 | AMC | -1.03 | -1.13 | -9.7% | 34.65 | +1.4% | +5.9% | +7.8% | +10.0% | +7.6% | +6.5% | — |
| May 12, 2025 | AMC | -1.19 | -0.95 | +20.2% | 39.58 | +1.2% | +0.4% | +0.7% | +2.7% | +2.6% | +0.8% | — |
| Mar 3, 2025 | AMC | -0.94 | -1.19 | -26.6% | 31.39 | -2.3% | -3.2% | +0.1% | +12.9% | +15.1% | +19.6% | — |
| Nov 12, 2024 | AMC | -0.88 | -0.86 | +2.2% | 57.35 | -0.1% | -8.0% | -11.1% | -17.6% | -21.0% | -18.9% | — |
| Aug 12, 2024 | AMC | -0.64 | -0.60 | +6.2% | 44.46 | -0.7% | -0.1% | -0.5% | +1.9% | +1.8% | +12.6% | — |
| May 13, 2024 | AMC | -0.60 | -0.64 | -6.7% | 52.73 | +1.9% | +2.4% | +1.1% | +1.9% | -4.6% | -0.6% | — |
| Mar 5, 2024 | AMC | -0.45 | -0.32 | +28.9% | 59.30 | +3.0% | +12.5% | +10.0% | +13.9% | +11.7% | +16.9% | — |
| Nov 13, 2023 | AMC | -0.38 | -0.51 | -34.2% | 16.28 | +2.1% | +5.1% | +9.7% | +3.3% | +12.4% | +10.7% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | Rothschild & Co Redburn | Initiates | Buy | $140 | $82.89 | $83.99 | +1.3% | -2.6% | — | — | — | — |
| Mar 30 | Mizuho | Maintains | Outperform → Outperform | — | $77.82 | $78.04 | +0.3% | +1.2% | +8.2% | +8.2% | +8.4% | +8.0% |
| Mar 24 | Canaccord Genuity | Maintains | Buy → Buy | — | $79.24 | $79.48 | +0.3% | -7.9% | -0.9% | -1.0% | -1.8% | -0.7% |
| Mar 24 | Citigroup | Maintains | Buy → Buy | — | $79.24 | $79.48 | +0.3% | -7.9% | -0.9% | -1.0% | -1.8% | -0.7% |
| Mar 24 | Guggenheim | Maintains | Buy → Buy | — | $79.24 | $79.48 | +0.3% | -7.9% | -0.9% | -1.0% | -1.8% | -0.7% |
| Mar 23 | BTIG | Maintains | Buy → Buy | — | $66.04 | $77.32 | +17.1% | +20.0% | +10.5% | +18.9% | +18.7% | +17.8% |
| Mar 16 | BTIG | Maintains | Buy → Buy | — | $71.90 | $72.01 | +0.2% | -1.1% | -2.9% | -7.1% | -4.7% | -8.2% |
| Mar 3 | Wedbush | Maintains | Outperform → Outperform | — | $70.92 | $68.78 | -3.0% | -3.4% | +2.0% | +0.0% | +3.0% | +5.7% |
| Mar 3 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $70.92 | $68.78 | -3.0% | -3.4% | +2.0% | +0.0% | +3.0% | +5.7% |
| Jan 22 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $81.91 | $79.98 | -2.4% | -2.5% | -14.5% | -14.5% | -11.6% | -13.7% |
Recent Filings
8-K · 5.02
!!! Very High
Apogee Therapeutics, Inc. -- 8-K 5.02: Executive Change
Apogee Therapeutics lost two directors, Andrew Gottesdiener and Peter Harwin, effective May 11, 2026, potentially signaling governance transition or underlying concerns about company direction.
Apr 24
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Underwriting / Securities
APGE entered an underwriting agreement with Jefferies, likely signaling an upcoming equity or debt offering that could dilute shareholders but provides capital for growth or debt management.
Mar 25
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
APGE's positive Phase 2 data for zumilokibart in Alzheimer's disease de-risks the pipeline and could support higher valuations if efficacy/safety profile remains compelling through later-stage trials.
Mar 23
8-K
Apogee Therapeutics, Inc. -- 8-K Filing
Apogee Therapeutics maintains strong cash reserves of $902.9 million extending runway to mid-2028, positioning the company to advance zumilokibart toward a potential 2029 launch while generating interim atopic dermatitis data.
Mar 2
Data updated apr 24, 2026 6:26pm
· Source: massive.com